PB-200a

PB-200a is an investigational **small-molecule antifungal** reportedly developed originally by UCB Celltech and later associated with IASO Pharma. Available pipeline sources describe it as a **1,3-beta-glucan synthase inhibitor**, implying a mechanism analogous to other fungal cell-wall biosynthesis inhibitors that block production of the essential fungal cell-wall polysaccharide beta-glucan. Publicly accessible information is sparse, and no clear evidence of regulatory approval, marketed branding, detailed clinical results, formulation, or route of administration was identified from broadly available sources. The program appears to have been explored for **fungal infections**, with some secondary market-report sources specifically mentioning **aspergillosis**, but the evidence base is limited and inconsistent.